References

• 2012Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States2,944 cited
• 2011The economic cost of brain disorders in Europe1,497 cited
• 2008Social anxiety disorder1,136 cited
• 2002Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale506 cited
• 2006Costs of nine common mental disorders: implications for curative and preventive psychiatry.386 cited
• 2005Size and burden of social phobia in Europe374 cited
• 2013Psychodynamic Therapy and Cognitive-Behavioral Therapy in Social Anxiety Disorder: A Multicenter Randomized Controlled Trial298 cited
• 2005Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation - ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG)226 cited
• 2002The economic consequences of social phobia181 cited
• 2008Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: A systematic review160 cited
• 1999Assessing the costs of healthcare technologies in clinical trials.150 cited
• 2008Economic costs of social phobia: A population-based study115 cited
• 2007Direct costs associated with depression in old age in Germany109 cited
• 2002A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.